Diabetology & Metabolic Syndrome最新文献

{"title":"Guardians of the sea: molecular and biochemical adaptations in sharks and whales for atherosclerosis resistance and their potential in human cardioprotection.","authors":"Raymond Rubianto Tjandrawinata, Isabela Caiado Caixeta Vencio, Axel Brahmantyo Maynardo Nugroho, Jonathan Hartanto, Nicolas Daniel Widjanarko, Fahrul Nurkolis","doi":"10.1186/s13098-025-01868-5","DOIUrl":"https://doi.org/10.1186/s13098-025-01868-5","url":null,"abstract":"<p><p>This review explores unique molecular and biochemical adaptations in sharks and whales that confer resistance to atherosclerosis despite high lipid concentrations, unlike atherosclerosis-prone terrestrial mammals (e.g., humans, primates) and shorter-lived marine species (e.g., seals, dolphins). Central to our hypothesis is that sharks and whales evolved unique lipid quality management, specialized peptide systems, and genomic expansions beyond ubiquitous marine omega-3 polyunsaturated fatty acids (PUFAs) to prevent plaque formation. Comparative lipidomics highlights marine-specific profiles rich in anti-inflammatory omega-3 PUFAs, contributing to vascular protection and plaque prevention. Sharks demonstrate potent anti-angiogenic peptides and aminosterols (e.g., squalamine, trodusquemine) that modulate key pathways like PTP1B inhibition, thus reducing inflammation and endothelial dysfunction. Whales exhibit specialized lipid metabolites in blubber, including esterified omega-3 PUFAs, enhancing antioxidant enzyme activity and endothelial nitric oxide production, crucial for maintaining vascular health. Genomic insights further reveal expanded antioxidant gene families in whales, highlighting potential translational strategies to human cardiovascular therapies. Future therapeutic strategies must resolve challenges in ethical sourcing, bioavailability, and scalability. CLINICAL TRIAL NUMBER: Not applicable.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"293"},"PeriodicalIF":3.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome.","authors":"Babi Dutta, Aparna Tripathy, P R Archana, Shobha U Kamath","doi":"10.1186/s13098-025-01837-y","DOIUrl":"https://doi.org/10.1186/s13098-025-01837-y","url":null,"abstract":"<p><p>The consumption of a high-fat high-calorie diet with or without fructose (western or cafeteria diet) increases body mass due to calorie excess, inducing glucolipid metabolism dysfunctions culminating in development of unhealthy obesity and metabolic syndrome (MetS). Understanding the sequelae of events that translates caloric excess to the development of MetS symptoms interlinking metabolic interrelationship between organs is paramount in the development of new treatment strategies. This review aims to create a compendium of evidence from mammalian studies (rodents, humans) to elucidate the metabolic changes induced by overnutrition. This review explores gut microbiome alterations, gut barrier dysfunctions, and immune dysregulation induced by a high-fat diet that changes gut tryptophan and biliary metabolism, which, with concomitant elevations in free fatty acids and ceramides, promote insulin insensitivity. Immunometabolic alteration induce adipose tissue dysfunction, which alters the secretion of adipokines and lipid metabolites that contribute to dyslipidemia, hepatosteatosis, cardiovascular dysfunction, and endocrine disruption. This review provides insights into the mechanism underlying unhealthy adipose expansion, shedding light on some of the exosome-mediated epigenomic alterations affecting obesity or MetS pathogenesis, which may help in the future design of microRNA biomarkers. The review also highlights areas where more supportive evidence may be needed to elucidate metabolic syndrome pathogenesis.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"292"},"PeriodicalIF":3.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus statement on standardizing CGM evaluation metrics in Latin America: an expert approach.","authors":"Mauro Scharf, Karen Feriz, Carlos Yepes, Álvaro Contreras, Lorena Lequi, David Sanhueza, Marcio Krakauer, Eduardo Márquez, Matías Ré, Roopa Mehta","doi":"10.1186/s13098-025-01851-0","DOIUrl":"10.1186/s13098-025-01851-0","url":null,"abstract":"<p><strong>Background: </strong>Latin America has no accepted performance standards for continuous glucose monitoring (CGM) technology evaluation. This has resulted in the emergence of various CGM devices in the market that do not meet strict quality, accuracy, reliability or safety standards. CGM systems are crucial for managing diabetes, as they provide frequent glucose measurements and help detect hypoglycemia or hyperglycemia episodes or even predict these events. Ensuring the reliability and accuracy of CGM devices is essential for patient safety. This consensus statement aims to establish a consensus-driven framework of expert recommendations regarding the metrics that should be evaluated to achieve high standards in CGM devices.</p><p><strong>Materials and methods: </strong>A modified Delphi methodology was employed, engaging endocrinologists, pediatric endocrinologists and diabetologists from Latin America. Experts participated in multiple rounds of surveys and discussions to reach consensus on key characteristics measures, including accuracy thresholds, clinical validation protocols, and post-market surveillance requirements. Quantitative and qualitative data were analyzed to ensure robust recommendations.</p><p><strong>Results: </strong>The expert panel identified major gaps in existing CGM regulations and established 12 key recommendations and one checklist to align Latin American standards with international best practices. These included the implementation of minimum accuracy thresholds, the adoption of standardized clinical validation protocols, and the enforcement of post-market surveillance measures. The panel also emphasized the importance of patient education, healthcare provider involvement in decision-making, and accessibility to enhance CGM adoption and usability. We underscore the necessity of these measures to improve patient outcomes, patient safety, and regulatory consistency in the region, while also enhancing CGM reliability and accuracy.</p><p><strong>Conclusion: </strong>This consensus statement highlights the urgent need for a standardized metrics to evaluate CGM devices in Latin America. Implementing standardized accuracy requirements, rigorous validation protocols, and enhanced patient education will ensure device reliability, improve clinical outcomes, and foster a more equitable healthcare landscape for diabetes management in the region.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"291"},"PeriodicalIF":3.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of sibutramine and topiramate for the treatment of obesity: the SIBAMATE retrospective cohort study : Sibutramine and topiramate for the treatment of obesity.","authors":"Cintia Cercato, Matheo A M Stumpf, Gabriel Neimann da Cunha Freire, Eduardo Zanatta Kawahara, Ariana E Fernandes, Maria E de Melo, Marcio C Mancini","doi":"10.1186/s13098-025-01842-1","DOIUrl":"10.1186/s13098-025-01842-1","url":null,"abstract":"<p><strong>Background: </strong>Long-term treatment of obesity with lifestyle changes alone is unsustainable for most individuals. Antiobesity medications are recommended for individuals with a body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² with one or more comorbidities. In Brazil, the prescription of combined sibutramine plus topiramate for obesity management is common in daily clinical practice. However, data on its effectiveness and safety are lacking. Thus, the objective of this study was to evaluate this combination for treating obesity in a real-world scenario.</p><p><strong>Methods: </strong>This retrospective cohort study included individuals with obesity ≥ 18 years prescribed sibutramine and topiramate for at least 3 months between 2012 and 2022 at a large tertiary healthcare center. Baseline and follow-up data were collected from medical records.</p><p><strong>Results: </strong>Among 861 medical records screened, 246 (28.6%) were included. Most participants were female (86.2%) with a mean age of 42.8 ± 12.7 years, 52% had hypertension, 31.3% type 2 diabetes and 30% dyslipidemia. The average baseline BMI and weight were 39.7 kg/m² and 104.2 kg, respectively. The mean daily doses of sibutramine and topiramate were 11 ± 2.1 mg and 119.7 ± 54.7 mg, respectively. There was a significant change in body weight precociously at 3 months on the combination (96.8 ± 20.7 kg, p < 0.001), with 61.8% of patients achieving at least ≥ 5% of weight loss, 29.4% ≥10% and 10.9% ≥15%. At 36 months, 64% maintained at least ≥ 5% of weight loss, 40.6% ≥10% and 26.5% ≥15%. Common adverse effects included paresthesia, memory impairment, bradyphrenia and elevated blood pressure. The discontinuation rate was 24.4%. No major safety concern was observed in a mean follow-up of 25.3 months.</p><p><strong>Conclusion: </strong>In a real-world setting, sibutramine and topiramate combination therapy was associated with clinically meaningful weight loss alongside a good tolerability profile.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"289"},"PeriodicalIF":3.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of concurrent continuous aerobic and short rest resistance exercise training on metabolic biomarkers in type 2 diabetes patients: a systematic review and meta-analysis.","authors":"Friew Amare, Alemmebrat Kiflu, Aschenaki Taddese","doi":"10.1186/s13098-025-01838-x","DOIUrl":"10.1186/s13098-025-01838-x","url":null,"abstract":"","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"290"},"PeriodicalIF":3.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of vitamin E administration on serum lipid profile in diabetic patients: a grade-assessed systematic review and dose-response meta-analysis of RCTs.","authors":"Mehdi Karimi, Mohammad Amin Karimi, Farzad Fayedeh, Fatemeh Ziyafati Kafi, Kimia Kazemi, Sharareh Jahangiri, Omid Asbaghi","doi":"10.1186/s13098-025-01833-2","DOIUrl":"10.1186/s13098-025-01833-2","url":null,"abstract":"<p><strong>Background: </strong>Diabetes is often associated with dyslipidemia, increasing the risk of cardiovascular complications. Studies have shown that Vitamin E, as a potent antioxidant, may improve serum lipid profile by reducing oxidative stress and inflammation. However, findings on its effects on diabetic patients remain inconsistent. To address this gap, this meta-analysis aims to evaluate the impact of vitamin E on serum lipid parameters in individuals with diabetes.</p><p><strong>Methods: </strong>A search was conducted on databases from inception to June 2025 to identify relevant randomized controlled trials (RCTs). Pooled effect sizes were estimated using weighted mean differences (WMDs) with 95% confidence intervals (CIs), applying a random-effects model. All statistical analyses were performed using STATA (V. 11.2).</p><p><strong>Results: </strong>The pooled analysis of 28 RCTs found that overall vitamin E administration in diabetic patients significantly reduced total cholesterol (TC) (WMD: - 5.20 mg/dL, 95% CI: [- 7.60, - 2.80], p < 0.001) and low-density lipoprotein cholesterol (LDL-C) (WMD: - 4.21 mg/dL, 95% CI: [- 7.32, - 1.09], p = 0.008). While no significant change was observed in triglyceride (TG) (WMD: - 6.19 mg/dL, 95% CI: [- 13.13, 0.75], p = 0.081) and high-density lipoprotein cholesterol (HDL-C) serum levels (WMD: 0.57 mg/dL, 95%CI: [- 0.11, 1.24], p = 0.99). Subgroup analysis showed that vitamin E reduced TG with longer durations, lowered TC and LDL-C in participants with high baseline levels, higher doses, or longer interventions, and increased HDL-C only in studies lasting over 8 weeks. Linear regression analysis found no significant associations between vitamin E dose or duration and serum lipids. In contrast, non-linear dose-response analysis showed a significant inverse relationship between vitamin E dose and TC levels.</p><p><strong>Conclusion: </strong>Vitamin E administration may improve lipid profiles in diabetic patients, with significant reductions in TC and LDL-C, while effects on TG and HDL-C were not statistically significant but showed potential clinical relevance. Subgroup analysis highlighted greater benefits with higher doses (> 400 IU/day) and longer intervention durations (> 8 weeks), particularly in individuals with elevated baseline lipid levels. Further large-scale studies are needed to confirm these findings and establish optimal dosing strategies for clinical application.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"280"},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When climate crisis hits home: mental health of elderly with type 2 diabetes amidst floods in Brazil.","authors":"Marcell Machado Cipolat, Lucas Strassburger Matzenbacher, Laura Gomes Boabaid de Barros, Ana Gabriela Rodrigues Haussen, Mariana Kude Perrone, Helena Toniazzi Uchôa, Bianca Gomes Corrêa, Vicenzo Gheno, Frederico Ludwig da Costa, Gabriela Heiden Telo","doi":"10.1186/s13098-025-01576-0","DOIUrl":"10.1186/s13098-025-01576-0","url":null,"abstract":"<p><strong>Background: </strong>Climate change has increased the frequency of natural disasters, challenging society in various aspects. Individuals living with chronic diseases are particularly vulnerable due to their constant need for medical care. This study aimed to investigate the impact of the unprecedented floods that hit Brazil in 2024 on the mental health of elderly with diabetes.</p><p><strong>Methods: </strong>This is a cross-sectional study involving outpatient elderly individuals with type 2 diabetes in Southern Brazil. Participants were stratified into two groups according to the impact their residences suffered from the floods (directly vs. non-directly impacted). The study outcome was mental distress, assessed using the Self-Report Questionnaire-20 (SRQ-20). Analyses of covariance and multivariable logistic regression were used for between-group comparisons.</p><p><strong>Results: </strong>A total of 80 elderly individuals were included, with a mean age of 72.5 ± 5.5 years old. Among the participants, 67.5% were women, and 57.5% were white. Fifty individuals were directly affected by the floods, while 30 were non-directly impacted. When compared, SRQ-20 scores were significantly higher in the directly impacted group, with an adjusted mean difference of 2.56 (95% CI: 0.42-4.70; p = 0.020), indicating higher mental distress among those directly impacted. Additionally, the prevalence of positive screening for mental distress was higher among those directly impacted by the floods (58% vs. 30%; adjusted OR = 4.16 [95% CI = 1.40-12.31], p = 0.010).</p><p><strong>Conclusions: </strong>Our findings highlight the significant prevalence of mental distress among those directly impacted by climate disasters, underscoring the need for public policies and strategies focused on mental health during and after such disasters.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"285"},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Every 1,000 steps matter: incremental reductions in metabolic syndrome risk in Japanese office workers.","authors":"Yukako Yamaga, Thomas Svensson, Ung-Il Chung, Akiko Kishi Svensson","doi":"10.1186/s13098-025-01816-3","DOIUrl":"10.1186/s13098-025-01816-3","url":null,"abstract":"<p><strong>Background: </strong>Several studies have investigated the association between metabolic syndrome (MetS) and physical activity (PA). However, further research is needed using objective measures of PA in free-living conditions, while also accounting for the time-variant nature of MetS. This study aimed to: (1) investigate the association between wearable device-measured step count and 5-year MetS incidence in generally healthy Japanese participants, using annual health check-up (AHC) data and interval-censored survival analysis; and (2) assess the current, and recently revised, reference value (8,000 steps/day) of Japan's Ministry of Health, Labour and Welfare (MHLW), and (3) investigate the possibility of non-linear associations between daily step count and MetS.</p><p><strong>Methods: </strong>This longitudinal prospective observation study identified average daily step count per year/person as the main exposure, and MetS incidence, defined according to Japanese guidelines, as the main outcome. The main analysis included 730 participants without MetS or pre-MetS at baseline. An interval-censored Cox model was applied to assess MetS incidence using time-to-event data.</p><p><strong>Results: </strong>Every 1,000 steps added to the average step count was significantly and inversely associated with incident MetS in adjusted models [Model 1: HR = 0.92; 95% CI: 0.85, 1.00; Model 2: HR = 0.91; 95% CI: 0.83, 0.99] (p < 0.05). The current reference value (8,000 steps/day) also indicated a significant inverse association [Model 1: HR = 0.32; 95% CI: 0.14, 0.71; Model 2: HR = 0.26; 95% CI: 0.11, 0.61] (p < 0.01). Higher daily step counts lowered the risk of MetS incidence according to the amount of steps up to a step count of 12,000, however, the dose-response effect was attenuated beyond 12,000 steps/day.</p><p><strong>Conclusions: </strong>Each additional 1,000 daily steps was associated with a 9% reduction in the risk of developing MetS among healthy participants. The reference value (8,000 steps/day) was associated with a 74% reduction in MetS risk.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"281"},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remnant cholesterol predicts the development of type 2 diabetes in patients with nonalcoholic fatty liver disease.","authors":"Liping Yang, Hangkai Huang, Zejun Wang, Chengfu Xu","doi":"10.1186/s13098-025-01828-z","DOIUrl":"10.1186/s13098-025-01828-z","url":null,"abstract":"<p><strong>Background: </strong>The predictive value of serum remnant cholesterol in cardiovascular disease has been widely recognized. This value has also been explored in metabolic disorders such as type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). However, whether remnant cholesterol can predict the risk of incident diabetes in NAFLD patients remains unclear.</p><p><strong>Methods: </strong>This study included adults who underwent health examinations from 2004 to 2015. NAFLD was diagnosed via abdominal ultrasonography with the exclusion of other causes of chronic liver disease. Cox proportional hazards regression analyses were performed to investigate the associations between baseline remnant cholesterol and diabetes risk in NAFLD patients and NAFLD-free participants.</p><p><strong>Results: </strong>A total of 15,464 participants were included in this study, and 2,741 adults had NAFLD. During the 93,537 person-years of follow-up, 233 cases and 150 cases of incident diabetes were recorded among NAFLD patients and NAFLD-free individuals, respectively. Compared with the first quartile, the fourth quartile of remnant cholesterol was positively associated with the risk of diabetes in NAFLD patients (HR: 1.68, 95% CI: 1.13 - 2.51; P < 0.001). However, this association was not significant in NAFLD-free individuals.</p><p><strong>Conclusions: </strong>High remnant cholesterol was associated with an increased risk of incident diabetes in NAFLD patients but not in NAFLD-free individuals.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"277"},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidimensional links between dietary behavior and cardiometabolic comorbidities: a network analysis.","authors":"Yiyan Wang, Yiwen Cao, Xiaoling Zhou, Ying Liu, Jing Wu, Ming Li","doi":"10.1186/s13098-025-01853-y","DOIUrl":"10.1186/s13098-025-01853-y","url":null,"abstract":"<p><strong>Background: </strong>The burden of cardiometabolic comorbidities-such as hypertension, diabetes, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD)-attributable to unhealthy dietary behaviors is increasing, particularly among working-age populations. This study aimed to investigate the complex interactions between dietary behaviors and cardiometabolic comorbidities using network analysis.</p><p><strong>Methods: </strong>This cross-sectional study enrolled 1,427 corporate employees aged 18-50 years in Shanghai, China, who underwent routine health check-ups from July to December 2022. Demographic characteristics and dietary behaviors were assessed via a self-reported questionnaire, while metabolic indicators were obtained through clinical evaluations. Mixed graphical models were used to construct a network identifying associations among demographic factors, unhealthy dietary behaviors, and six cardiometabolic comorbidities: hypertension, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, hyperuricemia, and NAFLD.</p><p><strong>Results: </strong>Among participants, 49.5% had at least one cardiometabolic comorbidity. Network analyses revealed that interactions among demographic factors, various dietary behaviors, and cardiometabolic comorbidities formed a complex structure, with frequent meat consumption (2.03) and eating out (2.00) exhibiting high centrality in the network. Further sensitivity analyses indicated that eating before bedtime (2.01) emerged as a central node when modifiable demographic factors were included in the model.</p><p><strong>Conclusions: </strong>This study identifies specific unhealthy dietary behaviors that are strongly linked to early manifestations of cardiometabolic comorbidities in working-age adults. The findings suggest that these behaviors may serve as effective targets for dietary interventions and public health strategies aimed at metabolic disease prevention.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"278"},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}